Fundación Jiménez Díaz

Running trials

• Recruiting

  Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

  NCT07478991· Phase 3· Source

• Not yet recruiting

  Optimizing the Use of Aspirin for the Prevention of Preeclampsia

  NCT07665853· Phase 3· Source

• Recruiting

  Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

  NCT07507760· Phase 2· Source

• Recruiting

  AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  NCT07094113· Phase 1· Source

• Recruiting

  Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  NCT06324357· Phase 1/2· Source

• Recruiting

  HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

  NCT06236269· Phase 2· Source

• Recruiting

  A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  NCT06179160· Phase 1· Source

• Recruiting

  Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

  NCT07159750· Source

• Recruiting

  Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

  NCT06095583· Phase 3· Source

• Recruiting

  Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

  NCT03994471· Phase 3· Source

• Active, not recruiting

  Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

  NCT04994795· Source

• Active, not recruiting

  Investigating Bone Cement With or Without Inossia® Cement Softener for Vertebral Compression Fractures

  NCT05676320· Source

• Recruiting

  Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

  NCT04179929· Source

• Active, not recruiting

  SyncAV Post-Market Trial

  NCT04100148· Source

• Recruiting

  Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK

  NCT04181970· Source

• Recruiting

  Thoracic Tumours Register

  NCT02941458· Source

• Recruiting

  Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

  NCT01574053· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer3 recruiting
• Lung cancer3 recruiting
• Acute myeloid leukemia2 recruiting
• Metastatic breast cancer2 recruiting
• Pancreatic cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Gastric and esophageal cancer1 recruiting
• Huntington's disease1 recruiting
• Migraine1 recruiting
• Sarcoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma

  NCT07354282· Source

• Completed

  Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units".

  NCT06159894· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Source

• Completed

  Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

  NCT04826003· Phase 1· Source

• Completed

  A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

  NCT04543617· Phase 3· Source

• Completed

  MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

  NCT04495621· Phase 1/2· Source

• Completed

  A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04256421· Phase 3· Source

• Completed

  Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

  NCT04075825· Phase 3· Source

• Terminated

  An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

  NCT03779113· Phase 1· Source

• Completed

  Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

  NCT04107727· Phase 2· Source

• Completed

  Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

  NCT03250338· Phase 3· Source

• Completed

  Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

  NCT03547908· Phase 3· Source

• Completed

  Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

  NCT03112174· Phase 3· Source

• Completed

  This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

  NCT03099174· Phase 1· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· Source

• Completed

  An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

  NCT01853826· Phase 3· Source